Achieve Life Sciences Inc. (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments. It's showing strong recent technical momentum. The Trend Seeker issued a new “Buy” signal on June 25 and the stock has gained 16.8% since then, writes Jim Van Meerten, analyst at Barchart.
ACHV has surged 173% over 52 weeks. Shares hit a three-year high in July. I found the stock by screening for names with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. ACHV checks those boxes.
Achieve Life Sciences Inc. (ACHV)
Achieve Life Sciences has a Weighted Alpha of 122.1. The stock recently traded at $6.62 with a 50-day moving average of $6. ACHV has made 13 new highs and features a 60-month beta of 2.2. The Relative Strength Index (RSI) is at 58.7.
The Wall Street analysts followed by Barchart give the stock eight “Strong Buy” opinions with price targets between $10 and $21. ACHV is highly speculative. But analysts predict it may begin to monetize its research soon.
